Cardiovasc Endocrinol Metab. 2021 Aug 19;10(4):193-203. doi: 10.1097/XCE.0000000000000253. eCollection 2021 Dec.
With the ongoing distribution of the coronavirus disease (COVID) vaccines, the pandemic of our age is ending, leaving the world to deal with its well-documented aftereffects. Long COVID comprises a variety of symptoms, of which the neurological component prevails. The most permeating theory on the genesis of these symptoms builds upon the development of microvascular dysfunction similar to that seen in numerous vascular diseases such as diabetes. This can occur through the peripheral activation of angiotensin-converting enzyme 2 receptors, or through exacerbations of pro-inflammatory cytokines that can remain in circulation even after the infection diminishes. Several drugs have been identified to act on the neurovascular unit to promote repair, such as gliptins, and others. They also succeeded in improving neurologic outcome in diabetic patients. The repurposing of such drugs for treatment of long COVID-19 can possibly shorten the time to recovery of long COVID-19 syndrome.
随着新冠病毒病（COVID）疫苗的持续分发，我们这个时代的大流行即将结束，世界将着手应对有充分记录的后遗症。长期新冠有多种症状，其中神经方面的症状最为突出。关于这些症状成因的最普遍理论基于微血管功能障碍的发展，类似于在糖尿病等多种血管疾病中所见。这可能通过血管紧张素转换酶2受体的外周激活发生，或者通过促炎细胞因子的加剧发生，即使感染减轻后这些细胞因子仍可在循环中存在。已确定几种药物作用于神经血管单元以促进修复，如格列汀等。它们还成功改善了糖尿病患者的神经结局。将此类药物重新用于治疗长期新冠可能会缩短长期新冠综合征的恢复时间。
